First Patient Enrolled In FDA-Approved Clinical Trial Of CBD-Based Drug For Treatment Of PTSD

The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology, for post-traumatic stress disorder.

The trial is being led by principal investigator Matthew Rizzo, MD, FAAN, FANA, Frances & Edgar Reynolds chair, professor of the UNMC Department of Neurological Sciences, chief physician for neurological services at Nebraska Medicine, and chief physician for neurosciences clinical programs at Nebraska Medicine.

“We are very excited to have this important trial underway,” stated Dr. Rizzo. “Our collaboration with ANANDA Scientific is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population.”

Dr. Rizzo’s research team includes Jennifer Merickel, PhD, cognitive neuroscientist and assistant professor in the UNMC Department of Neurological Sciences, and Brigette Soltis-Vaughan, an advanced practice registered nurse, clinician and researcher in the UNMC Department of Psychiatry and instructor in the UNMC Department of Neurological Sciences.

“Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” stated Sohail R. Zaidi, ANANDA’s CEO. “We are very pleased to be partnering with the UNMC’s research team in evaluating our promising drug for this very debilitating condition.”

This phase II double-blind, placebo-controlled, randomized clinical study is planning to enroll 180 participants to provide rigorous evaluation of the efficacy and safety of Nantheia ATL5.

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo: Benzinga edit with photo by Roxana Gonzalez on Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.